May 22, 2017May 22, 2017

Galecto’s Inhaled IPF Therapy Candidate Shows Early Promise in Clinical Trial

Inhaled therapy candidate TD139 shows promise in treating idiopathic pulmonary fibrosis (IPF) patients, Galecto Biotech reports. The results came from a Phase 1b/2a clinical trial (NCT02257177) evaluating TD139 in two parts. Phase 1b was ... Read more

March 16, 2017March 16, 2017

Galecto’s TD139 Shows Promise in IPF Patients, Clinical Trial Shows

Idiopathic Pulmonary Fibrosis, News

Galecto Biotech has completed a Phase 1b/2a clinical trial that indicated its inhaled therapy candidate TD139 shows promise in treating idiopathic pulmonary fibrosis (IPF) patients. TD139 is an inhibitor of galectin-3, ... Read more